Conditions: Psoriatic Arthritis
Keywords: Psoriatic Arthritis Brodalumab AMG 827
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 484
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Detailed description:

Arms:
arm 1: Administered via subcutaneous injections. arm 2: Administered via subcutaneous injection. arm 3: Administered via subcutaneous injection until week 24.

Interventions: intervention 1: 210 mg brodalumab intervention 2: 140 mg brodalumab intervention 3: Placebo
Intervention descriptions: intervention 1: 210 mg brodalumab administered via subcutaneous injection. intervention 2: 140 mg brodalumab administered via subcutaneous injection. intervention 3: Placebo administered via subcutaneous injection until week 24.

Protocol document: